Human Genome Epidemiology Literature Finder
Records 1 - 30 (of 31 Records) |
Query Trace: Fatigue and MET[original query] |
---|
The relationship between a common catechol-O-methyltransferase (COMT) polymorphism val(158) met and fibromyalgia. Clinical and experimental rheumatology 0 27 (5 Suppl 56): S51-6. Cohen H, Neumann L, Glazer Y, Ebstein R P, Buskila |
Catechol-O-methyltransferase genotype (Val158met) modulates cancer-related fatigue and pain sensitivity in breast cancer survivors. Breast cancer research and treatment 2012 Jun 133 (2): 405-12. Fernández-de-las-Peñas César, Fernández-Lao Carolina, Cantarero-Villanueva Irene, Ambite-Quesada Silvia, Rivas-Martínez Inés, del Moral-Avila Rosario, Arroyo-Morales Manu |
Influence of catechol-o-methyltransferase genotype (Val158Met) on endocrine, sympathetic nervous and mucosal immune systems in breast cancer survivors. Breast (Edinburgh, Scotland) 2012 Apr 21 (2): 199-203. Fernández-de-Las-Peñas César, Cantarero-Villanueva Irene, Fernández-Lao Carolina, Ambite-Quesada Silvia, Díaz-Rodríguez Lourdes, Rivas-Martínez Inés, del Moral-Avila Rosario, Arroyo-Morales Manu |
Dopaminergic polymorphisms associated with time-on-task declines and fatigue in the Psychomotor Vigilance Test. PloS one 2012 7 (3): e33767. Lim Julian, Ebstein Richard, Tse Chun-Yu, Monakhov Mikhail, Lai Poh San, Dinges David F, Kwok Kenne |
Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2013 Jan 31 (2): 181-6. Choueiri Toni K, Vaishampayan Ulka, Rosenberg Jonathan E, Logan Theodore F, Harzstark Andrea L, Bukowski Ronald M, Rini Brian I, Srinivas Sandy, Stein Mark N, Adams Laurel M, Ottesen Lone H, Laubscher Kevin H, Sherman Laurie, McDermott David F, Haas Naomi B, Flaherty Keith T, Ross Robert, Eisenberg Peter, Meltzer Paul S, Merino Maria J, Bottaro Donald P, Linehan W Marston, Srinivasan Ramapras |
The effect of CYP2C19 polymorphism on the safety, tolerability, and pharmacokinetics of tivantinib (ARQ 197): results from a phase I trial in advanced solid tumors. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2013 Jun 24 (6): 1653-9. Yamamoto N, Murakami H, Nishina T, Hirashima T, Sugio K, Muro K, Takahashi T, Naito T, Yasui H, Akinaga S, Koh Y, Boku |
Brain-derived neurotrophic factor serum levels and genotype: association with depression during interferon-a treatment. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 2013 May 38 (6): 985-95. Lotrich Francis E, Albusaysi Salwa, Ferrell Robert |
Polymorphism in COMT is associated with IgG3 subclass level and susceptibility to infection in patients with chronic fatigue syndrome. Journal of translational medicine 2015 13 (1): 264. Löbel Madlen, Mooslechner Agnes Anna, Bauer Sandra, Günther Sabrina, Letsch Anne, Hanitsch Leif G, Grabowski Patricia, Meisel Christian, Volk Hans-Dieter, Scheibenbogen Carm |
Cabozantinib for the treatment of progressive metastatic medullary thyroid cancer. Expert review of clinical pharmacology 2015 Nov 1-11. Krajewska Jolanta, Olczyk Tomasz, Jarzab Barba |
A phase I study of tivantinib in combination with temsirolimus in patients with advanced solid tumors. Investigational new drugs 2016 Dec . Kyriakopoulos Christos E, Braden Amy M, Kolesar Jill M, Eickhoff Jens C, Bailey Howard H, Heideman Jennifer, Liu Glenn, Wisinski Kari |
Crizotinib achieves long-lasting disease control in advanced papillary renal-cell carcinoma type 1 patients with MET mutations or amplification. EORTC 90101 CREATE trial. European journal of cancer (Oxford, England : 1990) 2017 11 87 147-163. Schöffski Patrick, Wozniak Agnieszka, Escudier Bernard, Rutkowski Piotr, Anthoney Alan, Bauer Sebastian, Sufliarsky Jozef, van Herpen Carla, Lindner Lars H, Grünwald Viktor, Zakotnik Branko, Lerut Evelyne, Debiec-Rychter Maria, Marréaud Sandrine, Lia Michela, Raveloarivahy Tiana, Collette Sandra, Albiges Lauren |
A phase I study of foretinib plus erlotinib in patients with previously treated advanced non-small cell lung cancer: Canadian cancer trials group IND.196. Oncotarget 2017 Sep 8 (41): 69651-69662. Leighl Natasha B, Tsao Ming-Sound, Liu Geoffrey, Tu Dongsheng, Ho Cheryl, Shepherd Frances A, Murray Nevin, Goffin John R, Nicholas Garth, Sakashita Shingo, Chen Zhuo, Kim Lucia, Powers Jean, Seymour Lesley, Goss Glenwood, Bradbury Penelope |
A systematic review of the association between fatigue and genetic polymorphisms. Brain, behavior, and immunity 2017 1 62 230-244. Wang Tengteng, Yin Jie, Miller Andrew H, Xiao Canh |
Randomized phase 2 study of tivantinib plus erlotinib versus single-agent chemotherapy in previously treated KRAS mutant advanced non-small cell lung cancer. Lung cancer (Amsterdam, Netherlands) 2018 Mar 117 44-49. Gerber David E, Socinski Mark A, Neal Joel W, Wakelee Heather A, Shirai Keisuke, Sequist Lecia V, Rosovsky Rachel P, Lilenbaum Rogerio C, Bastos Bruno R, Huang Chao, Johnson Melissa L, Hesketh Paul J, Subramaniam Deepa S, Dietrich Martin F, Chai Feng, Wang Yunxia, Kazakin Julia, Schwartz Brian, Schiller Joan H, Brahmer Julie R, Kelly Ronan |
Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial. The Lancet. Oncology 2020 9 21 (10): 1296-1308. Turner Nicholas C, Kingston Belinda, Kilburn Lucy S, Kernaghan Sarah, Wardley Andrew M, Macpherson Iain R, Baird Richard D, Roylance Rebecca, Stephens Peter, Oikonomidou Olga, Braybrooke Jeremy P, Tuthill Mark, Abraham Jacinta, Winter Matthew C, Bye Hannah, Hubank Michael, Gevensleben Heidrun, Cutts Ros, Snowdon Claire, Rea Daniel, Cameron David, Shaaban Abeer, Randle Katrina, Martin Sue, Wilkinson Katie, Moretti Laura, Bliss Judith M, Ring Alista |
Brain-derived neurotrophic factor polymorphism Val66Met protects against cancer-related fatigue. Translational psychiatry 2020 Aug 10 (1): 302. Feng Li Rebekah, Juneau Paul, Regan Jeniece M, Liwang Josephine, Alshawi Sarah, Wang Angela, Saligan Leorey |
A mutation-specific, single-arm, phase 2 study of dovitinib in patients with advanced malignancies. Oncotarget 2020 4 11 (14): 1235-1243. Taylor Matthew H, Alva Ajjai S, Larson Timothy, Szpakowski Sebastian, Purkaystha Das, Amin Alpesh, Karpiak Linda, Piha-Paul Sarina |
Phase II Trial of Cabozantinib in Recurrent/Metastatic Endometrial Cancer: A Study of the Princess Margaret, Chicago, and California Consortia (NCI9322/PHL86). Clinical cancer research : an official journal of the American Association for Cancer Research 2020 Jan . Dhani Neesha C, Hirte Hal W, Wang Lisa, Burnier Julia V, Jain Angela, Butler Marcus O, Welch Stephen, Fleming Gini F, Hurteau Jean, Matsuo Koji, Matei Daniela, Jimenez Waldo, Johnston Carolyn, Cristea Mihaela, Tonkin Katia, Ghatage Prafull, Lheureux Stephanie, Mehta Anjali, Quintos Judy, Tan Qian, Kamel-Reid Suzanne, Ludkovski Olga, Tsao Ming-Sound, Wright John J, Oza Amit |
Phase I Study of 2- or 3-Week Dosing of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, Monotherapy in Patients with Advanced Non-Small Cell Lung Carcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research 2021 8 27 (21): 5781-5792. Camidge D Ross, Morgensztern Daniel, Heist Rebecca S, Barve Minal, Vokes Everett, Goldman Jonathan W, Hong David S, Bauer Todd M, Strickler John H, Angevin Eric, Motwani Monica, Parikh Apurvasena, Sun Zhaowen, Bach Bruce Allen, Wu Jun, Komarnitsky Philip B, Kelly Kar |
Clinical and genetic factors associated with anxiety and depression in breast cancer patients: a cross-sectional study. BMC cancer 2021 Jul 21 (1): 872. Hajj Aline, Hachem Roula, Khoury Rita, Hallit Souheil, ElJEBBAWI Bashar, Nasr Fady, El Karak Fadi, Chahine Georges, Kattan Joseph, Rabbaa Khabbaz Lyd |
Savolitinib ± Osimertinib in Japanese Patients with Advanced Solid Malignancies or EGFRm NSCLC: Ph1b TATTON Part C. Targeted oncology 2021 5 16 (3): 339-355. Yoh Kiyotaka, Hirashima Tomonori, Saka Hideo, Kurata Takayasu, Ohe Yuichiro, Hida Toyoaki, Mellemgaard Anders, Verheijen Remy B, Ou Xiaoling, Ahmed Ghada F, Hayama Manabu, Sugibayashi Ko, Oxnard Geoffrey |
Phase I/II Study of Capmatinib Plus Erlotinib in Patients With MET-Positive Non-Small-Cell Lung Cancer. JCO precision oncology 2021 5 1 . McCoach Caroline E, Yu Aiming, Gandara David R, Riess Jonathan W, Vang Daniel P, Li Tiahong, Lara Primo N, Gubens Matthew, Lara Frances, Mack Philip C, Beckett Laurel A, Kelly Kar |
Fear of pain moderates the relationship between self-reported fatigue and methionine allele of catechol-O-methyltransferase gene in patients with fibromyalgia. PloS one 2021 16 (4): e0250547. Ferrera David, Mercado Francisco, Peláez Irene, Martínez-Iñigo David, Fernandes-Magalhaes Roberto, Barjola Paloma, Écija Carmen, Díaz-Gil Gema, Gómez-Esquer Francis |
Lurbinectedin, a selective inhibitor of oncogenic transcription, in patients with pretreated germline BRCA1/2 metastatic breast cancer: results from a phase II basket study. ESMO open 2022 8 7 (5): 100571. Boni V, Pistilli B, Braña I, Shapiro G I, Trigo J, Moreno V, Castellano D, Fernández C, Kahatt C, Alfaro V, Siguero M, Zeaiter A, Longo F, Zaman K, Antón A, Paredes A, Huidobro G, Subbiah |
Phase Ia/Ib Study of the Selective MET Inhibitor, Savolitinib, in Patients with Advanced Solid Tumors: ?Safety, Efficacy, and Biomarkers. The oncologist 2022 4 27 (5): 342-e383. Wang Yakun, Liu Tianshu, Chen Gongyan, Gong Jifang, Bai Yuxian, Zhang Tao, Xu Nong, Liu Li, Xu Jianming, He Jianxing, Liu Yunpeng, Zhang Li, Jiang Da, Wang Mengzhao, Chang Jianhua, Li Wei, Bai Chunmei, Zhou Jinghong, Wang Jian, Ren Yongxin, Zhang Liya, Su Weiguo, Liu Baorui, Shen L |
Olaparib outcomes in metastatic castration-resistant prostate cancer: First real-world experience in safety and efficacy from the Chinese mainland. Prostate international 2022 10 10 (3): 142-147. Pan Jian, Ye Dingwei, Zhu Y |
Predictors of Chronic Fatigue Syndrome and Mood Disturbance After Acute Infection. Frontiers in neurology 2022 13 935442. Sandler Carolina X, Cvejic Erin, Valencia Braulio M, Li Hui, Hickie Ian B, Lloyd Andrew |
Brain-derived neurotrophic factor as a biomarker in cancer-related cognitive impairment among adolescent and young adult cancer patients. Scientific reports 2023 9 13 (1): 16298. Ding Quan Ng, Ivy Cheng, Claire Wang, Chia Jie Tan, Yi Long Toh, Yong Qin Koh, Yu Ke, Koon Mian Foo, Raymond J Chan, Han Kiat Ho, Lita Chew, Mohamad Farid Bin Harunal Rashid, Alexandre Ch |
Brain-Derived Neurotrophic Factor rs6265 polymorphism is associated with severe cancer-related fatigue and neuropathic pain in female cancer survivors. Journal of cancer survivorship : research and practice 2023 7 . Taichi Goto, Diane Von Ah, Xiaobai Li, Lichen Xiang, Catherine Kwiat, Christopher Nguyen, Chao-Pin Hsiao, Leorey N Salig |
Association of COMT Val158Met Polymorphism with Fibromyalgia in Khartoum State, Sudan. Pain research & management 2023 6 2023 7313578. Safaa Mamoun Abdelmageid, Faisal Mousa Alamir, Hassan Yousif Abdelrahman, Hind Mohamed Abusha |
- Page last reviewed:Feb 1, 2024
- Page last updated:Apr 22, 2024
- Content source: